loading...| Preferred Name |
acitretin |
|
| Synonyms |
Trimethylmethoxyphenyl-retinoic acid |
|
| Definitions |
An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties. Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells. This agent may also inhibit tumor angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C985" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C985" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000043244 |
|
| altLabel |
Trimethylmethoxyphenyl-retinoic acid Neotigason Etretin (All-E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetraenoic Acid Ro-10-1670 Soriatane Ro 10-1670 |
|
| CAS Registry |
55079-83-9 |
|
| cui |
C0678135 C0050559 C4082602 C0733550 |
|
| definition |
An orally-active metabolite of the synthetic aromatic retinoic acid agent etretinate with potential antineoplastic, chemopreventive, anti-psoratic, and embryotoxic properties. Acitretin activates nuclear retinoic acid receptors (RAR), resulting in induction of cell differentiation, inhibition of cell proliferation, and inhibition of tissue infiltration by inflammatory cells. This agent may also inhibit tumor angiogenesis. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C985" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C985" NCI Thesaurus) |
|
| Legacy PDQ ID |
7710 |
|
| LT |
TRD |
|
| NCI ID |
C985 |
|
| notation |
CDR0000043244 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
acitretin |
|
| tui |
T109 T121 |